Feedback / Questions
zidesamtinib (NVL-520) - Nuvalent
https://www.streetinsider.com/PRNewswire/Nuvalent+Announces+Positive+Pivotal+Data+from+ARROS-1+Clinical+Trial+of+Zidesamtinib+for+TKI+Pre-treated+Patients+with+Advanced+ROS1-positive+NSCLC/24967401.html
Jun 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next